272. 進行性骨化性線維異形成症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 39 / 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate
Clementia Pharmaceuticals Inc, an Ipsen Company
2022 Phase 2 EUCTR2020-002858-24-SE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2020-002858-24-ES Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-NL Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-DE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate
CLEMENTIA PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-002858-24-IT Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
AZD0530
VU University Medical Center
2020 Phase 2 EUCTR2019-003324-20-NL Netherlands;
AZD0530 Difumarate
VU University Medical Center
2020 Phase 2 NCT04307953 Germany;Netherlands;United Kingdom;
DS-6016a
Daiichi Sankyo Co., Ltd.
2021 Phase 1 NCT04818398 Japan;
Garetosmab
Regeneron Pharmaceuticals
2021 Phase 3 NCT04577820 -
INCB000928
Incyte Corporation
2021 Phase 2 NCT05090891 -
INCB000928 fumarate dihydrate
Incyte Corporation
- Phase 2 EUCTR2021-002286-17-FR Australia;Brazil;Canada;France;Germany;Korea, Republic of;Netherlands;Russian Federation;United Kingdom;United States;
- Phase 2 EUCTR2021-002286-17-DE Australia;Brazil;Canada;France;Germany;Korea, Republic of;Netherlands;Russian Federation;United Kingdom;United States;
IPN60120
Ipsen Pharma
- Phase 3 EUCTR2021-002244-70-SE Argentina;Australia;Brazil;Canada;France;Italy;Spain;Sweden;United Kingdom;United States;
Ipsen Pharma SAS
- Phase 3 EUCTR2021-002244-70-FR Argentina;Australia;Brazil;Canada;France;Italy;Spain;Sweden;United Kingdom;United States;
IPN60130
Clementia Pharmaceuticals Inc.
2021 Phase 2 NCT05039515 France;Italy;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
IPN60130 10 mg capsules
CLEMENTIA PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-002858-24-IT Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Clementia Pharmaceuticals Inc, an Ipsen Company
2022 Phase 2 EUCTR2020-002858-24-SE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2020-002858-24-ES Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-NL Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-DE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
IPN60130 50 mg capsules
CLEMENTIA PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-002858-24-IT Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Clementia Pharmaceuticals Inc, an Ipsen Company
2022 Phase 2 EUCTR2020-002858-24-SE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2020-002858-24-ES Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-NL Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-DE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Midazolam
Clementia Pharmaceuticals Inc.
2019 Phase 1 NCT04829773 United States;
PALOVAROTENE -
Clementia Pharmaceuticals Inc
- Phase 3 EUCTR2017-002541-29-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
PALOVAROTENE-
CLEMENTIA PHARMACEUTICALS INC.
2018 Phase 3 EUCTR2017-002541-29-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
Palovarotene
Clementia Pharmaceuticals Inc.
2019 Phase 1 NCT04829773 United States;
2017 Phase 3 NCT03312634 Argentina;Australia;Brazil;Canada;France;Italy;Japan;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 NCT02979769 France;
2015 Phase 2 NCT02521792 France;United Kingdom;United States;
2015 Phase 2 EUCTR2014-002496-28-GB Argentina;Australia;United Kingdom;United States;
2014 Phase 2 NCT02190747 France;United Kingdom;United States;
- Phase 2 EUCTR2016-002526-36-FR France;
Ipsen
2022 Phase 3 NCT05027802 -
Palovarotene dose level 1
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 2
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 3
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 4
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Perhexiline
Nagoya University Graduate School of Medicine
2010 Phase 1,2 JPRN-UMIN000019348 Japan;
REGN2477
REGENERON PHARMACEUTICALS, INC.
2017 Phase 2 EUCTR2016-005035-33-IT Argentina;Brazil;France;Italy;Netherlands;United Kingdom;United States;
Regeneron Pharmaceuticals
2018 Phase 2 NCT03188666 Canada;Colombia;France;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Regeneron Pharmaceuticals, Inc.
2019 Phase 2 EUCTR2016-005035-33-ES Canada;Colombia;France;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-005035-33-NL Argentina;Brazil;France;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-005035-33-GB Canada;Colombia;France;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
SARACATINIB DIFUMARATE
VU University Medical Center
2020 Phase 2 EUCTR2019-003324-20-NL Netherlands;
Clementia Pharmaceuticals Inc, an Ipsen Company
2022 Phase 2 EUCTR2020-002858-24-SE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2020-002858-24-ES Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-NL Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-DE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate
CLEMENTIA PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-002858-24-IT Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
AZD0530
VU University Medical Center
2020 Phase 2 EUCTR2019-003324-20-NL Netherlands;
AZD0530 Difumarate
VU University Medical Center
2020 Phase 2 NCT04307953 Germany;Netherlands;United Kingdom;
DS-6016a
Daiichi Sankyo Co., Ltd.
2021 Phase 1 NCT04818398 Japan;
Garetosmab
Regeneron Pharmaceuticals
2021 Phase 3 NCT04577820 -
INCB000928
Incyte Corporation
2021 Phase 2 NCT05090891 -
INCB000928 fumarate dihydrate
Incyte Corporation
- Phase 2 EUCTR2021-002286-17-FR Australia;Brazil;Canada;France;Germany;Korea, Republic of;Netherlands;Russian Federation;United Kingdom;United States;
- Phase 2 EUCTR2021-002286-17-DE Australia;Brazil;Canada;France;Germany;Korea, Republic of;Netherlands;Russian Federation;United Kingdom;United States;
IPN60120
Ipsen Pharma
- Phase 3 EUCTR2021-002244-70-SE Argentina;Australia;Brazil;Canada;France;Italy;Spain;Sweden;United Kingdom;United States;
Ipsen Pharma SAS
- Phase 3 EUCTR2021-002244-70-FR Argentina;Australia;Brazil;Canada;France;Italy;Spain;Sweden;United Kingdom;United States;
IPN60130
Clementia Pharmaceuticals Inc.
2021 Phase 2 NCT05039515 France;Italy;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
IPN60130 10 mg capsules
CLEMENTIA PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-002858-24-IT Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Clementia Pharmaceuticals Inc, an Ipsen Company
2022 Phase 2 EUCTR2020-002858-24-SE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2020-002858-24-ES Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-NL Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-DE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
IPN60130 50 mg capsules
CLEMENTIA PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-002858-24-IT Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Clementia Pharmaceuticals Inc, an Ipsen Company
2022 Phase 2 EUCTR2020-002858-24-SE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 2 EUCTR2020-002858-24-ES Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-NL Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2020-002858-24-DE Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Midazolam
Clementia Pharmaceuticals Inc.
2019 Phase 1 NCT04829773 United States;
PALOVAROTENE -
Clementia Pharmaceuticals Inc
- Phase 3 EUCTR2017-002541-29-DE Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
PALOVAROTENE-
CLEMENTIA PHARMACEUTICALS INC.
2018 Phase 3 EUCTR2017-002541-29-IT Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
Palovarotene
Clementia Pharmaceuticals Inc.
2019 Phase 1 NCT04829773 United States;
2017 Phase 3 NCT03312634 Argentina;Australia;Brazil;Canada;France;Italy;Japan;Spain;Sweden;United Kingdom;United States;
2016 Phase 2 NCT02979769 France;
2015 Phase 2 NCT02521792 France;United Kingdom;United States;
2015 Phase 2 EUCTR2014-002496-28-GB Argentina;Australia;United Kingdom;United States;
2014 Phase 2 NCT02190747 France;United Kingdom;United States;
- Phase 2 EUCTR2016-002526-36-FR France;
Ipsen
2022 Phase 3 NCT05027802 -
Palovarotene dose level 1
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 2
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 3
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 4
Clementia Pharmaceuticals Inc.
2014 Phase 2 NCT02279095 Argentina;Australia;France;United Kingdom;United States;
Perhexiline
Nagoya University Graduate School of Medicine
2010 Phase 1,2 JPRN-UMIN000019348 Japan;
REGN2477
REGENERON PHARMACEUTICALS, INC.
2017 Phase 2 EUCTR2016-005035-33-IT Argentina;Brazil;France;Italy;Netherlands;United Kingdom;United States;
Regeneron Pharmaceuticals
2018 Phase 2 NCT03188666 Canada;Colombia;France;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Regeneron Pharmaceuticals, Inc.
2019 Phase 2 EUCTR2016-005035-33-ES Canada;Colombia;France;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-005035-33-NL Argentina;Brazil;France;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-005035-33-GB Canada;Colombia;France;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
SARACATINIB DIFUMARATE
VU University Medical Center
2020 Phase 2 EUCTR2019-003324-20-NL Netherlands;